Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 (vol 15, pg 429, 2009)

被引：2
|
作者：
Junttila, Teemu T. [1 ]
Akita, Robert W. [1 ]
Parsons, Kathryn [1 ]
Fields, Carter [1 ]
Phillips, Gail D. Lewis [1 ]
Friedman, Lori S. [1 ]
Sampath, Deepak [1 ]
Sliwkowski, Mark X. [1 ]
机构：
[1] Genentech Inc, Res Oncol, San Francisco, CA 94080 USA
来源：
CANCER CELL | 2011年 / 20卷 / 06期
关键词：
D O I：
10.1016/j.ccr.2011.12.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：818 / 818
页数：1
相关论文
共 50 条
  • [31] Changes in plasma components β-oxidation as a pharmacodynamic (PD) biomarker of PI3K inhibition by GDC-0941, a potent, pan-inhibitor of Class I phosphatidyl-inositol-3-kinase (PI3K)
    Ang, Joo Ern
    Pandher, Rupinder
    Asad, Yasmin
    Henley, Alan
    Valenti, Melanie
    Box, Gary
    Brandon, Alexis de Haven
    Eccles, Suzan
    Workman, Paul
    de Bono, Johann S.
    Raynaud, Florence I.
    CANCER RESEARCH, 2013, 73 (08)
  • [32] Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer
    Poovassery, Jayakumar S.
    Kang, Jeffrey C.
    Kim, Dongyoung
    Ober, Raimund J.
    Ward, E. Sally
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (02) : 267 - 277
  • [33] Resistance against the irreversible dual EGFR/HER2 inhibitor pelitinib (EKB-569) correlates with hyperactive HER3/PI3K/AKT signaling
    Shabbir, Waheed
    Bruenner-Kubath, Caroline
    Grusch, Michael
    Berger, Walter
    Marian, Brigitte
    Singer, Christian
    Wagner, Renate
    Zielinski, Christoph
    Grunt, Thomas
    CANCER RESEARCH, 2009, 69
  • [34] Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
    Hoeflich, Klaus P.
    Merchant, Mark
    Orr, Christine
    Chan, Jocelyn
    Den Otter, Doug
    Berry, Leanne
    Kasman, Ian
    Koeppen, Hartmut
    Rice, Ken
    Yang, Nai-Ying
    Engst, Stefan
    Johnston, Stuart
    Friedman, Lori S.
    Belvin, Marcia
    CANCER RESEARCH, 2012, 72 (01) : 210 - 219
  • [35] Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling
    Usman, Muhammad Waqas
    Gao, Jing
    Zheng, Tiezheng
    Rui, Chunhua
    Li, Ting
    Bian, Xing
    Cheng, Hailing
    Liu, Pixu
    Luo, Fuwen
    CELL DEATH & DISEASE, 2018, 9
  • [36] Combined Targeting of the PI3K Pathway and HER2 Overcomes Acquired and De Novo Trastuzumab Resistance
    O'Brienl, N. A.
    McDonald, K.
    Von, Euw E.
    Conklin, D.
    Kalous, O.
    Di Tomaso, E.
    Finn, R. S.
    Slamon, D. J.
    CANCER RESEARCH, 2011, 71
  • [37] The PI3K Inhibitor GDC-0941 Attenuates Disease in a KrasG12D Mouse Model of CMML and JMML.
    Akutagawa, Jon
    Dail, Monique
    Friedman, Lori S.
    Shannon, Kevin M.
    Sampath, Deepak
    Braun, Benjamin S.
    BLOOD, 2012, 120 (21)
  • [38] Pre-clinical evaluation of efficacy and PK/PD biomarkers of GDC-0941, a potent class 1 PI3K inhibitor
    Patel, S.
    Sampath, D.
    Belvin, M.
    Brown, A.
    Edgar, K.
    Lensun, L.
    Moore, P.
    Salphati, L.
    Stern, H.
    Friedman, L.
    EJC SUPPLEMENTS, 2008, 6 (12): : 69 - 69
  • [39] Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling
    Muhammad Waqas Usman
    Jing Gao
    Tiezheng Zheng
    Chunhua Rui
    Ting Li
    Xing Bian
    Hailing Cheng
    Pixu Liu
    Fuwen Luo
    Cell Death & Disease, 9
  • [40] Transient pAkt increase after chemo exposure predicts strength of synergy for combinations of the PI3K inhibitor GDC-0941 and chemotherapeutics
    Wallin, Jeffrey
    Edgar, Kyle
    Guan, Jane
    Friedman, Lori
    Belvin, Marcia
    CANCER RESEARCH, 2009, 69
12345